{"id":"W2980670340","doi":"10.1016/j.jtho.2019.10.006","title":"Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non–Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Ignyta; EMD Serono; Eisai; Natera; Ariad Pharmaceuticals; Genentech; Bristol-Myers Squibb; AstraZeneca; Pfizer; Novartis Pharmaceuticals Corporation; Chugai Pharmaceutical; Daiichi-Sankyo","keywords":"Ceritinib; Medicine; Nivolumab; Cohort; Internal medicine; Lung cancer; Gastroenterology; Cancer; Anaplastic lymphoma kinase; Oncology; Immunotherapy; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004060956,0.0001885945,0.0008810385,0.0002362664,0.00004423111,0.00001716999,0.0002749824,0.00009387586,0.00005159102],"category_scores_gemma":[0.00004150105,0.0001385973,0.00004110414,0.000243855,0.0000405438,0.0003329473,0.00006643154,0.0003353414,0.000002810621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008715061,"about_ca_system_score_gemma":0.001096718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004825233,"about_ca_topic_score_gemma":0.0008199815,"domain_scores_codex":[0.9981052,0.0001975939,0.000844107,0.0002760567,0.0003091471,0.0002679146],"domain_scores_gemma":[0.9978181,0.00008527048,0.001024119,0.0003166196,0.00056215,0.0001938053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2668718,0.1150424,0.2669612,0.0004886122,0.001226753,0.000910615,0.01333086,0.0006071832,0.005067227,9.23341e-7,0.000464154,0.3290283],"study_design_scores_gemma":[0.5829816,0.1716865,0.2278994,0.001408561,0.002563105,0.00005117882,0.007218678,0.0009351566,0.001857247,0.000004132759,0.003020885,0.0003735367],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941588,0.0002933656,0.00001454476,0.0002710179,0.0004891559,0.00255966,0.00008230403,0.000006318377,0.002124838],"genre_scores_gemma":[0.9941646,0.00005586172,0.004946329,0.0001331229,0.00006902993,0.00004487151,0.00003636207,0.00003183651,0.0005179984],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3286548,"threshold_uncertainty_score":0.5651835,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02181959936904216,"score_gpt":0.4505129397924997,"score_spread":0.4286933404234576,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}